[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cns-vasculitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cns-vasculitis":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,75],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100495684","longitudinal-study-for-central-nervous-system-vasculitis-100495684",false,"NCT05734404","Longitudinal Study for Central Nervous System Vasculitis","Inclusion Criteria:\n\ni. Diagnostic criteria for CNSV\n\n1. The presence of an acquired and otherwise unexplained neurologic deficit\n2. The presence of either classic angiographic or histopathologic features of angiitis in the CNS\n3. No evidence of systemic vasculitis or any condition that could cause the angiographic or pathologic features\n\nii. ≥18 years of age\n\nExclusion Criteria:\n\ni. Unwilling to sign informed consent.","ALL","18 Years",{"count":18,"type":19},40,"ESTIMATED","OBSERVATIONAL","Primary central nervous system vasculitis (CNSV) is a potentially fatal, single-organ vasculitis that often involves a spectrum of neurologic complications, including strokes, cognitive and speech impairment, visual loss, dementia, and encephalopathy. The purpose of this study is to establish a research cohort to investigate the disease process, treatments, and patient outcomes in CNSV.",[23,24,25,26],"Central Nervous System Vasculitis","CNS Vasculitis","CNSV","Vasculitis","RECRUITING","2026-01-21",{"date":30,"type":31},"2026-01-23","ACTUAL",{"date":33,"type":31},"2023-03-01",{"date":35,"type":19},"2030-12-31",{"name":37,"class":38},"University of Pennsylvania","OTHER",6,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":48,"minAge":16,"maxAge":49,"enrollmentInfo":50,"targetDuration":52,"studyType":20,"phases":4,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":68,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},"100254637","vasculitis-pregnancy-registry-100254637","NCT02593565","Vasculitis Pregnancy Registry","The Vasculitis Pregnancy Registry (V-PREG)","V-PREG","Inclusion Criteria:\n\n1. Women 18 years of age or older with one of the following diseases may take part in the study:\n\n   * Behçet's disease;\n   * Central nervous system (CNS) vasculitis;\n   * Cryoglobulinemic vasculitis (Cryoglobulinemia);\n   * Eosinophilic granulomatosis with polyangiitis (also called Churg-Strauss Syndrome);\n   * Giant Cell (Temporal) Arteritis (GCA);\n   * Granulomatosis with polyangiitis (also called Wegener's);\n   * IgA vasculitis (Henoch-Schoenlein purpura);\n   * Microscopic polyangiitis (MPA);\n   * Polyarteritis nodosa (PAN);\n   * Takayasu's arteritis (TAK);\n   * Urticarial vasculitis;\n   * Other\u002FSuspected Diagnosis.\n2. Women must be pregnant (self-report) at the time of enrollment into the registry.\n\nExclusion Criteria:\n\n1. Non-English speaking, with the exception of people who speak Spanish, Portuguese, Italian, or Turkish.\n2. Unable to provide consent.","FEMALE","50 Years",{"count":51,"type":19},100,"12 Months","The purpose of this study is to learn about the experience of women with vasculitis who become pregnant. In particular, the study will consist of several online surveys to assess\n\n1. each woman's vasculitis severity and pregnancy-related experiences, and\n2. pregnancy outcomes.",[26,55,24,56,57,58,59,60,61,62,63,64,65,66,67],"Behcet's Disease","Cryoglobulinemic Vasculitis","Eosinophilic Granulomatosis With Polyangiitis (EGPA)","Churg-Strauss Syndrome (CSS)","Granulomatosis With Polyangiitis (GPA)","Wegener's Granulomatosis","IgA Vasculitis","Henoch-Schoenlein Purpura (HSP)","Microscopic Polyangiitis (MPA)","Polyarteritis Nodosa (PAN)","Takayasu Arteritis (TAK)","Urticarial Vasculitis","Systemic Vasculitis",{"date":30,"type":31},{"date":70,"type":4},"2015-11",{"date":72,"type":19},"2027-12",{"name":37,"class":38},1,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":82,"enrollmentInfo":83,"targetDuration":16,"studyType":20,"phases":4,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":113},"100440580","swiss-pediatric-inflammatory-brain-disease-registry-swiss-ped-ibraind-100440580","NCT05017142","Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)","Swiss Pediatric Inflammatory Bain Disease Cohort Study","Inclusion Criteria:\n\nAll patients living and\u002For treated in Switzerland with an IBrainD specified in the following list diagnosed from 2005 onward and with a disease onset before the age of 18.\n\n* Written informed consent by patients (and\u002For legal representative(s), if applicable)\n* Optic Neuritis\n* Transverse Myelitis\n* Acute disseminated encephalomyelitis\n* Multiple Sclerosis\n* Neuromyelitis Optica Spectrum Disorders\n* Myelin oligodendrocyte glycoprotein antibody-associated disease\n* Anti-NMDA-R Encephalitis\n* Anti-GAD65 Associated Autoimmune Encephalitis\n* Anti-AMPAR-1\u002F2 Associated Autoimmune Encephalitis\n* Anti-Lgi-1 Associated Autoimmune Encephalitis\n* Anti-CASPR-2 Associated Autoimmune Encephalitis\n* Anti-GABAR-1\u002F2 Associated Autoimmune Encephalitis\n* Onconeuronal Antibody (Hu, Ri, Yo, Amphiphysin, CRMP-5, Ma-1, Ma-2, SOX-1) Associated Autoimmune Encephalitis\n* Hashimoto Encephalopathy\n* CNS Vasculitis\n* CNS Sarcoidosis\n* CNS Lupus\n* Rasmussen Encephalitis\n\nExclusion Criteria:\n\n* Neurological symptoms due to infectious diseases of the CNS\n* Genetic\u002Fmetabolic causes of central demyelinating diseases\n* Neurological symptoms due to Guillain-Barré-Syndrome","36 Years",{"count":84,"type":19},500,"The Swiss-Ped-IBrainD is a national patient registry that collects information on diagnosis, symptoms, treatment, and follow-up of pediatric patients with an inflammatory brain disease in Switzerland. It was first implemented in 2020 in the pediatric clinic of the university hospital in Bern. Further centers all over Switzerland opened for recruitment after that: Aarau, Basel, Bellinzona, Chur, Geneva, Lausanne, Lucerne, St. Gallen, Winterthur and Zurich. The center in Fribourg is expected open for recruitment in 2025. The registry provides data for national and international monitoring and research. It supports research on inflammatory brain diseases in Switzerland and the exchange of knowledge between clinicians, researchers, and therapists. The registry aims to improve the treatment of children with inflammatory brain diseases and optimizing their health care and quality of life.",[87,88,89,90,91,92,93,94,95,96,97,98,99,24,100,101,102,103],"Optic Neuritis","Transverse Myelitis","Acute Disseminated Encephalomyelitis","Multiple Sclerosis","Neuromyelitis Optica Spectrum Disorder","Anti-NMDAR Encephalitis","Anti-GAD65 Associated Autoimmune Encephalitis","Anti-AMPAR-1\u002F2 Associated Autoimmune Encephalitis","Anti-Lgi-1 Associated Autoimmune Encephalitis","Anti-CASPR-2 Associated Autoimmune Encephalitis","Anti-GABAR-1\u002F2 Associated Autoimmune Encephalitis","Onconeuronal Antibody (Hu, Ri, Yo, Amphiphysin, CRMP-5, Ma-1, Ma-2, SOX-1) Associated Autoimmune Encephalitis","Hashimoto Encephalitis","CNS Sarcoidosis","CNS Lupus","Rasmussen Encephalitis","Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)","2024-12-11",{"date":106,"type":31},"2024-12-16",{"date":108,"type":31},"2020-04-14",{"date":110,"type":19},"2071-01-01",{"name":112,"class":38},"University of Bern",13]